Avalo Therapeutics, Inc. 10-Q filing
Filed 2025-08-07 · Report date 2025-06-30 · 2025
Filing metadata
- Accession number
- 0001628280-25-038575
- Form type
- 10-Q
- CIK
- 0001534120
- Primary document
- https://www.sec.gov/Archives/edgar/data/1534120/000162828025038575/avtx-20250630.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Avalo Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Cost Of Revenue | $0 | - | - |
| Operating Income | $-34.0M | - | - |
| Net Income | $-33.9M | - | - |
| Eps Basic | -3.18 | - | - |
| Eps Diluted | -3.18 | - | - |
| Cash And Equivalents | $42.3M | - | - |
| Total Assets | $126.6M | - | - |
| Total Liabilities | $22.0M | - | - |
| Shareholders Equity | $104.6M | - | - |
| Operating Cash Flow | $-20.8M | - | - |